Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Ho

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Science (New York, N.Y.)|July 23, 2013
Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesityMasato Asai, Shwetha Ramachandrappa, Maria Joachim, et al.
Journal of Medicinal Chemistry|December 23, 2010
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Molecular and Cellular Biochemistry|July 15, 2011
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Science (New York, N.Y.)|July 23, 2013
Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesityMasato Asai, Shwetha Ramachandrappa, Maria Joachim, et al.
Journal of Medicinal Chemistry|December 23, 2010
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Molecular and Cellular Biochemistry|July 15, 2011
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Pageof 2